Dr. Goy on precision medicine updates in hematological malignancies

Dr. Goy on precision medicine updates in hematological malignancies

Andre H. Goy, MD, discusses updates in precision medicine.

Andre H. Goy, MD, Chief Medical Officer, Hackensack Meridian Health Oncology Care Transformation Service, Chairman and Chief Medical Officer, John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chair in Oncology, Hackensack Meridian School of Medicine at the University Seton Hall, Professor of Medicine, Georgetown University, discusses updates in precision medicine.

The use of CAR T-cell therapy, such as axicabtagene ciloleucel (axi-cel; Yescarta) has been shown to be beneficial in hematological malignancies, and it is important to understand that this has the potential to be a therapy curative, says Goy. Oncologists need to ensure patients are referred early in order to get the most benefit from this treatment, Goy says.

Additionally, when looking at patients in space, it must be understood that oncologists continue to investigate beyond a single cell type in order to reset the immune system in a suppressive environment induced by cancer cells, concludes Goy.

#Goy #precision #medicine #updates #hematological #malignancies

Leave a Comment

Your email address will not be published.